US EditionPublished • loading... • Updated
Trial of Light Therapy Device for Parkinson's Disease Fully Enrolled
Summary by Parkinson's News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Trial of light therapy device for Parkinson's disease fully enrolled
Photopharmics has completed enrollment of a Phase 3 clinical trial testing Celeste, its light therapy device for Parkinson’s disease, the company announced. The ongoing Phase 3 trial (NCT04453033), dubbed Light for PD, has enrolled 350 participants with Parkinson’s, surpassing the initial target enrollment of 300 patients. Topline results from the trial are expected in the second quarter of 2026. “Exceeding our target and closing enrollment is a…
FDA Clears Phase 2a Clinical Trial to Test JOTROL in Patients With Parkinson Disease | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Jupiter Neurosciences advances Parkinson treatment with FDA clearance for JOTROL's phase 2a trial, showcasing promising safety and bioavailability results.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
